Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: Results of a Canadian, multicenter, double-blind, placebo-controlled trial

Multiple Sclerosis

Volumn 15, Issue 10, 2009, Pages 1183-1194

  Metz, L M ^f   Li, D ^b   Traboulsee, A ^b   Myles, M L ^c   Duquette, P ^d   Godin, J ^e   Constantin, M ^e   Yong, V W ^a   Yeung, M M C ^a   Patry, D G ^a   Zabad, R K ^a   Stenerson, P E ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d NOTRE DAME HOSPITAL   (Canada)

^e Teva Neuroscience   (Canada)

^f NONE

Author keywords

Clinical trial; Glatiramer acetate; Magnetic resonance imaging; Minocycline; Multiple sclerosis; Tetracycline

Indexed keywords

GLATIRAMER; MINOCYCLINE; PLACEBO;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; CANADA; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; HERPES SIMPLEX; HUMAN; HYPERPIGMENTATION; INFLUENZA; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE MASS; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; INSOMNIA; LIVER DYSFUNCTION; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; THORAX PAIN; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTI-BACTERIAL AGENTS; BRAIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MINOCYCLINE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72449159325     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509106779     Document Type: Article

References (19)

1. 1. Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2004; 55: 756. (Pubitemid 38544341)
2. Zabad RK, Metz LM, Todoruk TR, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007; 13: 517-526.
3. 3. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408-414. (Pubitemid 17131177)
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.
5. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50: 701-708.
6. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo- controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-297.
7. McFarland HF, Reingold SC. The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. Mult Scler 2005; 6: 669-676.
8. European Medicines Agency. 'Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis', Document CPMP/EWP/561/98 Revision 1, http://www.emea.eu.int/pdfs/human/ewp/56198en.pdf. (2006, accessed 27 February 2007).
9. 9. Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol 2005; 158: 213-221. (Pubitemid 39626089)
10. 10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231. (Pubitemid 13158528)
11. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
12. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-1053.
13. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004; 3: 744-751.
14. Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001; 50: 646-657.
15. 15. Cassiani-Ingoni R, Muraro PA, Magnus T, et al. Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol 2007; 66: 637-649. (Pubitemid 47051709)
16. Beers DR, Henkel JS, Xiao Q, et al. Wild-type microglia extend survival in PU.l knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2006; 103: 16021-16026.
17. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005; 6: 931-944.
18. 18. Zhou H, Lapointe BM, Clark SR, Zbytnuik L, Kubes P. A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide. J Immunol 2006; 177: 8103-8110. (Pubitemid 44846329)
19. 19. Zhang Y, Metz LM, Yong VW, et al. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci 2008; 35: 185-191. (Pubitemid 351831055)